Essential thrombocythemia: diagnosis and treatment, with special emphasis on the use of anagrelide.
Andersson
Borje S
BS
UT MD Anderson Cancer Center, Houston, TX 77030, USA.
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001792:Blood Platelets / Q000187:drug effects; D000075202:Contraindications; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use; D013920:Thrombocythemia, Essential / Q000175:diagnosis* / Q000188:drug therapy*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D010975:Platelet Aggregation Inhibitors; D011799:Quinazolines; C021139:anagrelide